The mix of induced pluripotent stem (iPS) cell technology and targeted gene adjustment by homologous recombination (HR) represents a promising new method of generate genetically corrected patient-derived cells that might be useful for autologous transplantation therapies. mutations. Right here we explain the era of iPS cell lines from sickle cell anemia sufferers and correction from… Continue reading The mix of induced pluripotent stem (iPS) cell technology and targeted